Bluejay Therapeutics Stock

www.bluejaytx.comHealthcare / BioTech & PharmaFounded: 2019

Bluejay Therapeutics is a biopharmaceutical company that is striving to develop treatments for chronic viral infections and liver disease, particularly chronic hepatitis B virus (HBV) infections. Bluejay Therapeutics was founded in 2019 by Dr. Keting Chu and is headquartered in San Mateo, CA. The company is aiming to reduce hepatitis B surface antigen (HBsAg) levels with the goal of restoring antiviral immunity for patients.

Register To Buy and Sell Shares

For more details on financing and valuation for Bluejay Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Bluejay Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Bluejay Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Keting Chu Ph.D
Founder & Chief Executive Officer
Hassan Javanbakht Ph.D
Chief Scientific Officer
Nancy Shulman
Chief Medical Officer
Christopher Holterhoff
Senior Vice President, Head of Business Development
Kevin Lin
Vice President, Development
Jeff Zablocki
Vice President, Chemistry

Board Members

Alon Lazarus Ph.D
Arkin Bio Ventures
Pascal Krotee Ph.D
RiverVest Venture Partners
Ting Jia Ph.D
Octagon Capital Advisors
Wen Chen
Yonjin Venture
William Rutter

Frequently Asked Questions About Bluejay Therapeutics’ Stock

Can you buy Bluejay Therapeutics’ stock?
Bluejay Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Bluejay Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Bluejay Therapeutics’ stock?
Yes, you can sell stock of a private company like Bluejay Therapeutics. Forge can help you sell your Bluejay Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Bluejay Therapeutics’ stock price?
Bluejay Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Bluejay Therapeutics’ private market stock price with Forge Data.
What is Bluejay Therapeutics’ stock ticker symbol?
Bluejay Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
In a series C funding led by Frazier Life Sciences, RA Capital Management, T., and others helped Bluejay raise $182 million for its clinical pipeline.
Updated on: May 25, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.